+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05875168

Open-label Study of DS-3939a Administered by Intravenous Infusion to Adults With Advanced Solid Tumors Including Dose Escalation and Expansion Phases

Led by Daiichi Sankyo · Updated on 2026-10-15

590

Participants Needed

61

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating DS-3939a, an antibody drug conjugate ADC, for safety, tolerability, and effectiveness in adults with advanced solid tumors, including locally advanced, metastatic, or unresectable cancers. This first-in-human phase 12 clinical trial is divided into two parts dose escalation and dose expansion, focusing on participants with measurable disease and good performance status. Participants will receive DS-3939a as an intravenous infusion every 3 weeks on Day 1 of each 21-day cycle. The study includes a dose escalation part where dosing starts at 1 mgkg and a dose expansion part with multiple cohorts targeting various advanced solid tumors. Treatment continues with monitoring for dose-limiting toxicities and response rates over approximately 31 months. During the study, participants will undergo assessments including tumor biopsies, echocardiograms, and laboratory tests to monitor organ function and immune response. Researchers will track adverse events, tumor response, and pharmacokinetics through scheduled visits and sample collections. The study may last up to nearly 5 years, including treatment and follow-up periods, to evaluate long-term safety and efficacy outcomes.

CONDITIONS

Brief Title

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Research Team

(

(US Sites) Daiichi Sankyo Contact for Clinical Trial Information

(

(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here